NovaBridge Biosciences Changes Name to Reflect Strategic Transformation to Global Biotech Platform.
ByAinvest
Wednesday, Oct 29, 2025 9:06 am ET1min read
IMAB--
NovaBridge Biosciences has changed its name to reflect its strategic transformation into a global biotech platform. The company plans a Hong Kong IPO and dual listings on Nasdaq and HKEX, aiming to broaden access to global capital and innovation. NovaBridge has formed a new subsidiary, Visara, which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 for wet AMD and DME treatment. The company's core asset, givastomig, continues to advance under previously announced investment plans.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet